Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: travoprost Clear all
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 2 Interventional

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

NCT01789736
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
21
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Nov 2, 2026, 9:27 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

NCT00121147
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome
Interventions
Travatan, Azopt, Alphagan P
Drug
Lead sponsor
Hermann Eye Center
Other
Eligibility
35 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
21
States / cities
Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2006 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 3 Interventional

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

NCT04061044
View directory record Official record
Conditions
Open Angle Glaucoma and Ocular Hypertension
Interventions
Ophthalmic Insert
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 2 Interventional Results available

Study of Exchange of Travoprost Intraocular Implant

NCT04615403
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Travoprost
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Hemet, California • Petaluma, California • Fort Collins, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 2, 2026, 9:27 PM EST
Not listed Phase 2 Interventional

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 4 Interventional

Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy

NCT00444665
View directory record Official record
Conditions
Glaucoma
Interventions
Travatan-Z
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Fridley, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Nov 2, 2026, 9:27 PM EST
Completed No phase listed Observational

Assessing Ocular Surface Changes After Changing Glaucoma Medications

NCT00554411
View directory record Official record
Conditions
Glaucoma, Monotherapy With Xalatan From 1 to 18 Months, Ocular Surface Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 4 Interventional Results available

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 3 Interventional

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

NCT00051181
View directory record Official record
Conditions
Glaucoma, Angle-Closure, Ocular Hypertension
Interventions
Travoprost (0.004%), Latanoprost (0.005%)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 2 Interventional Results available

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

NCT02754596
View directory record Official record
Conditions
Glaucoma Open-angle
Interventions
Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 1 Interventional Results available

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

NCT04360174
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
OTX-TIC
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Petaluma, California • Torrance, California • Roswell, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Nov 2, 2026, 9:27 PM EST
Terminated Phase 4 Interventional Results available

Effects of Anti-Glaucoma Medications on the Ocular Surface

NCT01315574
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 4 Interventional

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

NCT00061503
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Travoprost
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Call For Details, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 3 Interventional Results available

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

NCT03868124
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Nov 2, 2026, 9:27 PM EST
Recruiting No phase listed Observational

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

NCT07400926
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Interventions
Travoprost
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kenosha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 4 Interventional Results available

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

NCT00705757
View directory record Official record
Conditions
Glaucoma, Application Site Pigmentation Changes
Interventions
latanoprost, bimatoprost, travoprost
Drug
Lead sponsor
Summa Health System
Other
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Arlington Heights, Illinois • Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 2 Interventional Results available

Travoprost Five Day Posology Study

NCT01114893
View directory record Official record
Conditions
Open-angle Glaucoma (OAG), Ocular Hypertension
Interventions
Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 2, 2026, 9:27 PM EST
Recruiting Phase 4 Interventional

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT07228221
View directory record Official record
Conditions
Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg
Device · Drug
Lead sponsor
Jonathon Myers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 4 Interventional Results available

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

NCT00798694
View directory record Official record
Conditions
Glaucoma
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 2 Interventional

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT02312544
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
OTX-TP, Timolol
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Nov 2, 2026, 9:27 PM EST
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

NCT00468988
View directory record Official record
Conditions
Glaucoma
Interventions
Travatan® Z, Xalatan®
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Nov 2, 2026, 9:27 PM EST
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Nov 2, 2026, 9:27 PM EST